Mannitol
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Mannitol: From Osmotic Diuretic Use to Nephrogenic Syndrome of Inappropriate Antidiuresis
One-Sentence Summary
Mannitol's original indication cannot be confirmed from this evidence pack — no Finland market licenses and no mechanism-of-action record are currently available. The TxGNN model predicts a possible link to Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD), but this is currently supported by 0 clinical trials and only 1 general review article that does not specifically evaluate mannitol for this condition.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no approved indication text found in the evidence pack (0 Finland licenses on record) |
| Predicted New Indication | Nephrogenic Syndrome of Inappropriate Antidiuresis |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 |
| Finland Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for mannitol is not currently available in this evidence pack (flagged as a High-severity data gap). Based on general pharmacological knowledge, mannitol is an osmotic diuretic that draws free water into the vascular space and promotes renal excretion of water; this general property is the basis for the model's mechanistic link to NSIAD.
NSIAD is a rare congenital disorder caused by gain-of-function mutation of the V2 vasopressin receptor, producing hyponatremia that mimics SIADH. The repurposing rationale notes that mannitol's osmotic diuresis could theoretically raise serum sodium acutely, but this is not the standard-of-care treatment for NSIAD (fluid restriction or urea are standard). The single supporting publication (PMID 26706473) is a general review on pitfalls in evaluating hyponatremia — it does not report any actual mannitol efficacy data for NSIAD specifically.
Given this, the mechanistic plausibility is theoretical rather than evidence-based. It is also worth noting that all 10 TxGNN-predicted indications for mannitol in this evidence pack were rated "Hold," and several carry specific caveats worth flagging: the malignant-hyperthermia-related predictions (ranks 3–4, 7, 8, 10) may reflect confounding with dantrolene (mannitol is a common excipient/co-administered diluent for IV dantrolene, not an active MH therapy), and the nephrogenic diabetes insipidus prediction (rank 9) may reflect the opposite causal direction — mannitol is a recognized cause of nephrogenic diabetes insipidus symptoms rather than a treatment for it. This overall pattern suggests the model score alone is not yet a reliable signal for this drug.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 26706473 | 2016 | Review | European Journal of Internal Medicine | General review of common diagnostic pitfalls in hyponatremia evaluation; does not evaluate mannitol therapy specifically for NSIAD |
Finland Market Information
No marketing authorizations are on record for mannitol in Finland (0 licenses; market status: not marketed).
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-interaction data are not currently available in this evidence pack — the TFDA/Fimea label data gap is flagged as Blocking, and the DDI query returned no results.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction (NSIAD) rests on a theoretical mechanistic argument, not standard-of-care use, and is backed by a single non-specific review article with no clinical trials. Combined with the blocking gap in label/safety data and the drug's unconfirmed original-indication and non-marketed status in Finland, there is not yet sufficient evidence to advance past initial screening (S0).
To proceed, the following is needed:
- TFDA/Fimea package insert (warnings, contraindications) — currently a Blocking data gap
- Confirmed mechanism of action from DrugBank — currently a High-severity data gap
- Confirmed original indication / licensing history for mannitol in Finland
- Dedicated clinical or mechanistic studies directly evaluating mannitol in NSIAD (not general hyponatremia reviews)
- Drug interaction (DDI) dataset — current query returned no results
- Manual review to rule out confounding for the malignant-hyperthermia-related and nephrogenic-diabetes-insipidus predictions noted above
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.